Progestogens for preterm birth prevention: a systematic review and meta-analysis by drug route
详细信息 查看全文
- 作者：Digna R. Velez Edwards (1) (4)
Frances E. Likis (2) (3)
Jeffrey C. Andrews (1) (4)
Alison L. Woodworth (5)
Rebecca N. Jerome (6) (8)
Christopher J. Fonnesbeck (7)
J. Nikki McKoy (3)
Katherine E. Hartmann (1) (2) (4) - 关键词：Preterm birth ; Meta ; analysis ; Review ; Pregnancy ; Progestogen
- 刊名：Archives of Gynecology and Obstetrics
- 出版年：2013
- 出版时间：June 2013
- 年：2013
- 卷：287
- 期：6
- 页码：1059-1066
- 全文大小：261KB
- 参考文献：1. Behrman RE, Butler AS, Institute of Medicine (US) (2007) Committee on understanding premature birth and assuring healthy outcomes. Preterm birth: causes, consequences, and prevention. National Academies Press, Washington, xvi, 772
2. Borna S, Sahabi N (2008) Progesterone for maintenance tocolytic therapy after threatened preterm labour: a randomised controlled trial. Aust N Z J Obstet Gynaecol 48:58-3 CrossRef
3. Facchinetti F, Paganelli S, Comitini G, Dante G, Volpe A (2007) Cervical length changes during preterm cervical ripening: effects of 17-alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol 196:453 CrossRef
4. Noblot G, Audra P, Dargent D, Faguer B, Mellier G (1991) The use of micronized progesterone in the treatment of menace of preterm delivery. Eur J Obstet Gynecol Reprod Biol 40:203-09 CrossRef
5. Kauppila A, Hartikainen-Sorri AL, Janne O, Tuimala R, Jarvinen PA (1980) Suppression of threatened premature labor by administration of cortisol and 17 alpha-hydroxyprogesterone caproate: a comparison with ritodrine. Am J Obstet Gynecol 138:404-08
6. Brucker MC, Likis FE (2011) Steroid hormones. Pharmacology for Women’s Health
7. FDA approves drug to reduce risk of preterm birth in at-risk pregnant women (2011) United States Food and Drug Administration
8. Dodd JM, Flenady V, Cincotta R, Crowther CA (2006) Prenatal administration of progesterone for preventing preterm birth. Cochrane Database Syst Rev CD004947
9. Gallo MF, Grimes DA, Lopez LM, Schulz KF, d’Arcangues C (2008) Combination injectable contraceptives for contraception. Cochrane Database Syst Rev CD004568
10. Gallo MF, Nanda K, Grimes DA, Lopez LM, Schulz KF (2008) 20?μg versus >20?μg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev CD003989
11. Romero R, Nicolaides K, Conde-Agudelo A, Tabor A, O’Brien JM, Cetingoz E et al (2012) Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data. Am J Obstet Gynecol 206:124
12. Smith V, Devane D, Begley CM, Clarke M, Higgins S (2009) A systematic review and quality assessment of systematic reviews of randomised trials of interventions for preventing and treating preterm birth. Eur J Obstet Gynecol Reprod Biol 142:3-1 CrossRef
13. Likis FE, Andrews JC, Woodworth AL, Velez Edwards DR, Jerome RN, Fonnesbeck CJ et al (2012) Progestogens for prevention of preterm birth. Agency for Healthcare Research and Quality, Rockville
14. Gelman A, Carlin J, Stern H, Rubin DB (2004) Bayesian Data Analysis
15. Sutton A, Abrams K (2001) Bayesian methods in meta-analysis and evidence synthesis
16. Patil A, Huard D, Fonnesbeck C (2010) Bayesian stochastic modelling in python. J Stat Softw 35:1-0
17. Rode L, Klein K, Nicolaides KH, Krampl-Bettelheim E, Tabor A (2011) Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo-controlled trial on the effect of vaginal micronized progesterone. Ultrasound Obstet Gynecol 38:272-80 CrossRef
18. Serra V, Perales A, Meseguer J, Parrilla JJ, Lara C, Bellver J et al (2013) Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double-blind multicentre trial. BJOG Int J Obstet Gynaecol 120:50-7 CrossRef
19. Schulz KF, Chalmers I, Hayes RJ, Altman DG (1995) Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 273:408-12 CrossRef
20. Hadjigeorgiou E, Malamitsi-Puchner A, Lolis D, Lazarides P, Nicolopoulos D, Kaskarelis D (1982) Cardiovascular birth defects and antenatal exposure to female sex hormones. Dev Pharmacol Ther 5:61-7
21. Arikan I, Barut A, Harma M, Harma IM (2011) Effect of progesterone as a tocolytic and in maintenance therapy during preterm labor. Gynecol Obstet Invest 72:269-73 CrossRef
22. Briery CM, Veillon EW, Klauser CK, Martin RW, Chauhan SP, Magann EF et al (2009) Progesterone does not prevent preterm births in women with twins. South Med J 102:900-04 CrossRef
23. Caritis SN, Rouse DJ, Peaceman AM, Sciscione A, Momirova V, Spong CY et al (2009) Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial. Obstet Gynecol 113:285-92
24. Combs CA, Garite T, Maurel K, Das A, Porto M (2010) Failure of 17-hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double-blind, randomized clinical trial. Am J Obstet Gynecol 203:248 CrossRef
25. Combs CA, Garite T, Maurel K, Das A, Porto M (2011) 17-hydroxyprogesterone caproate for twin pregnancy: a double-blind, randomized clinical trial. Am J Obstet Gynecol 204:221 CrossRef
26. Facchinetti F, Dante G, Venturini P, Paganelli S, Volpe A (2008) 17alpha-hydroxy-progesterone effects on cervical proinflammatory agents in women at risk for preterm delivery. Am J Perinatol 25:503-06 CrossRef
27. Fonseca EB, Celik E, Parra M, Singh M, Nicolaides KH (2007) Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med 357:462-69 CrossRef
28. Glover MM, McKenna DS, Downing CM, Smith DB, Croom CS, Sonek JD (2011) A randomized trial of micronized progesterone for the prevention of recurrent preterm birth. Am J Perinatol 28:377-81 CrossRef
29. Grobman WA, Thom EA, Spong CY, Iams JD, Saade GR, Mercer BM et al (2012) 17 alpha-hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30?mm. Am J Obstet Gynecol 207:390 CrossRef
30. Hassan SS, Romero R, Vidyadhari D, Fusey S, Baxter JK, Khandelwal M et al (2011) Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 38:18-1 CrossRef
31. Ibrahim M, Mohamed Ramy AR, Younis MAF (2010) Progesterone supplementation for prevention of preterm labor: A randomized controlled trial. 15 Middle East. Fertility Soc J 1:39-1 CrossRef
32. Lim AC, Schuit E, Bloemenkamp K, Bernardus RE, Duvekot JJ, Erwich JJ et al (2011) 17alpha-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: a randomized controlled trial. Obstet Gynecol 118:513-20 CrossRef
33. Majhi P, Bagga R, Kalra J, Sharma M (2009) Intravaginal use of natural micronised progesterone to prevent pre-term birth: a randomised trial in India. J Obstet Gynaecol 29:493-98 CrossRef
34. Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH et al (2003) Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 348:2379-385 CrossRef
35. Norman JE, Mackenzie F, Owen P, Mactier H, Hanretty K, Cooper S et al (2009) Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double-blind, placebo-controlled study and meta-analysis. Lancet 373:2034-040 CrossRef
36. O’Brien JM, Adair CD, Lewis DF, Hall DR, Defranco EA, Fusey S et al (2007) Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 30:687-96 CrossRef
37. Rai P, Rajaram S, Goel N, Ayalur Gopalakrishnan R, Agarwal R, Mehta S (2009) Oral micronized progesterone for prevention of preterm birth. Int J Gynaecol Obstet 104:40-3 CrossRef
38. Rouse DJ, Caritis SN, Peaceman AM, Sciscione A, Thom EA, Spong CY et al (2007) A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins. N Engl J Med 357:454-61 CrossRef
39. Rozenberg P, Chauveaud A, Deruelle P, Capelle M, Winer N, Desbriere R et al (2012) Prevention of preterm delivery after successful tocolysis in preterm labor by 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial. Am J Obstet Gynecol 206:e1- CrossRef
40. Saleh Gargari S, Habibolahi M, Zonobi Z, Khani Z, Sarfjoo FS, Kazemi Robati A et al (2012) Outcome of vaginal progesterone as a tocolytic agent: Randomized clinical trial. ISRN Obstet Gynecol 2012:607906
41. Sharami SH, Zahiri Z, Shakiba M, Milani F (2010) Maintenance therapy by vaginal progesterone after threatened idiopathic preterm labor: a randomized placebo-controlled double-blind trial. Int J Fert Steril 4:45-0
42. Tan PC, King AS, Vallikkannu N, Omar SZ (2012) Single dose 17 alpha-hydroxyprogesterone caproate in preterm labor: a randomized trial. Arch Gynecol Obstet 285:585-90 CrossRef
43. Wood S, Ross S, Tang S, Miller L, Sauve R, Brant R (2012) Vaginal progesterone to prevent preterm birth in multiple pregnancy: a randomized controlled trial. J Perinat Med 40:593-99 CrossRef
44. Breart G, Lanfranchi M, Chavigny C, Rumeau-Rouquette C, Sureau C (1979) A comparative study of the efficiency of hydroxyprogesterone caproate and of chlormadinone acetate in the prevention of premature labor. Int J Gynaecol Obstet 16:381-84
45. Gonzalez-Quintero VH, Istwan NB, Rhea DJ, Smarkusky L, Hoffman MC, Stanziano GJ (2007) Gestational age at initiation of 17-hydroxyprogesterone caproate (17P) and recurrent preterm delivery. J Matern Fetal Neonatal Med 20:249-52 CrossRef
46. How HY, Barton JR, Istwan NB, Rhea DJ, Stanziano GJ (2007) Prophylaxis with 17 alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery: does gestational age at initiation of treatment matter? Am J Obstet Gynecol 197:260 CrossRef - 作者单位：Digna R. Velez Edwards (1) (4)
Frances E. Likis (2) (3)
Jeffrey C. Andrews (1) (4)
Alison L. Woodworth (5)
Rebecca N. Jerome (6) (8)
Christopher J. Fonnesbeck (7)
J. Nikki McKoy (3)
Katherine E. Hartmann (1) (2) (4)
1. Vanderbilt Epidemiology Center, Institute for Medicine and Public Health, 2525 West End Ave., Suite 600 6th Floor, Nashville, TN, 37203, USA
4. Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, TN, USA
2. Vanderbilt Evidence-based Practice Center, Institute for Medicine and Public Health, Nashville, TN, USA
3. Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
5. Department of Pathology, Microbiology and Immunology, Nashville, TN, USA
6. Department of Biomedical Informatics, Nashville, TN, USA
8. Eskind Biomedical Library, Vanderbilt University Medical Center, Nashville, TN, USA
7. Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA - ISSN：1432-0711
文摘
Purpose Progestogen has been investigated as a preventive intervention among women with increased preterm birth risk. Our objective was to systematically review the effectiveness of intramuscular (IM), vaginal, and oral progestogens for preterm birth and neonatal death prevention. Methods We included articles published from January 1966 to January 2013 and found 27 randomized trials with data for Bayesian meta-analysis. Results Across all studies, only vaginal and oral routes were effective at reducing preterm births (IM risk ratio [RR] 0.95, 95?% Bayesian credible interval [BCI]: 0.88-.03; vaginal RR 0.87, 95?% BCI: 0.80-.94; oral RR 0.64, 95?% BCI: 0.49-.85). However, when analyses were limited to only single births all routes were effective at reducing preterm birth (IM RR 0.77, 95?% BCI: 0.69-.87; vaginal RR 0.80, 95?% BCI: 0.69-.91; oral RR 0.66, 95?% BCI: 0.47-.84). Only IM progestogen was effective at reducing neonatal deaths (IM RR 0.78, 95?% BCI: 0.56-.99; vaginal RR 0.75, 95?% BCI: 0.45-.09; oral RR 0.72, 95?% BCI: 0.09-.74). Vaginal progestogen was effective in reducing neonatal deaths when limited to singletons births. Conclusions All progestogen routes reduce preterm births but not neonatal deaths. Future studies are needed that directly compare progestogen delivery routes.